Exposure to chemicals absorbed by the skin can threaten human health. In order to standardise the predictive testing of percutaneous absorption for regulatory purposes, the OECD adopted guideline 428, which describes methods for assessing absorption by using human and animal skin. In this study, a protocol based on the OECD principles was developed and prevalidated by using reconstructed human epidermis (RHE). The permeation of the OECD standard compounds, caffeine and testosterone, through commercially available RHE models was compared to that of human epidermis and animal skin. In comparison to human epidermis, the permeation of the chemicals was overestimated when using RHE. The following ranking of the permeation coefficients for testosterone was obtained: SkinEthic > EpiDerm, EPISKIN > human epidermis, bovine udder skin, pig skin. The ranking for caffeine was: SkinEthic, EPISKIN > bovine udder skin, EpiDerm, pig skin, human epidermis. The inter-laboratory and intra-laboratory reproducibility was good. Long and variable lag times, which are a matter of concern when using human and pig skin, did not occur with RHE. Due to the successful transfer of the protocol, it is now in the validation process.
LiebschM., & SpielmannH. (2002). Currently available in vitro methods used in regulatory toxicology. Toxicology Letters127, 127–134.
4.
SpielmannH. (2003). Validation and regulatory acceptance of new carcinogenicity tests. Toxicologic Pathology31, 54–59.
5.
OECD (2004). OECD Guidelines for the Testing of Chemicals, No. 427: Skin absorption: in vivo method, 8 pp. Paris, France: OECD.
6.
OECD (2004). OECD Guidelines for the Testing of Chemicals, No. 428: Skin absorption: in vitro method, 8 pp. Paris, France: OECD.
7.
OECD (2003). Guidance Document for the Conduct of Skin Absorption Studies. Series on testing assessment No. 28.Paris, France: OECD.
8.
LundehnJ. (1992). Uniform principles for safeguarding the health of applicators of plant protection products (uniform principles for operator protection). Mitteilungen aus der Biologischen Bundesanstalt 277, Berlin, Germany.
9.
van RavenzwaayB., & LeiboldE. (2004). The significance of in vitro rat skin absorption studies to human risk assessment. Toxicology in Vitro18, 219–225.
10.
OnukiM., YokoyamaK., KimuraK., SatoH., NordinR.B., NaingL., MoritaY., SakaiT., KobayashiY., & ArakiS. (2003). Assessment of urinary cotinine as a marker of nicotine absorption from tobacco leaves: a study on tobacco farmers in Malaysia. Journal of Occupational Health45, 140–145.
11.
RamseyJ.D., WoollenB.H., AutonT.R., & ScottR.C. (1994). The predictive accuracy of in vitro measurements for the dermal absorption of a lipophilic penetrant (fluazifop-butyl) through rat and human skin. Fundamental and Applied Toxicology23, 230–236.
12.
FrantzS.W., BallantyneB., BeskittJ.L., TallantM.J., & GrecoR.J. (1995). Pharmacokinetics of 2-ethyl-1,3-hexanediol. III. In vitro skin penetration comparisons using the excised skin of humans, rats and rabbits. Fundamental and Applied Toxicology28, 1–8.
13.
HewittP.G., PerkinsJ., & HotchkissS.A. (2000). Metabolism of fluroxypyr, fluroxypyr methyl ester, and the herbicide fluroxypyr methylheptyl ester. I: during percutaneous absorption through fresh rat and human skin in vitro.Drug Metabolism and Disposition28, 748–754.
14.
PontA.R., CharronA.R., & BrandR.M. (2004). Active ingredients in sunscreens act as topical penetration enhancers for the herbicide 2,4-dichlorophenoxyacetic acid. Toxicology and Applied Pharmacology195, 348–354.
15.
ScottR.C., BattenP.L., ClowesH.M., JonesB.K., & RamseyJ.D. (1992). Further validation of an in vitro method to reduce the need for in vivo studies for measuring the absorption of chemicals through rat skin. Fundamental and Applied Toxicology19, 484–492.
16.
QiaoG.L., & RiviereJ.E. (2002). Systemic uptake and cutaneous disposition of pentachlorophenol in a sequential exposure scenario: effects of skin preexposure to benzo[a]pyrene. Journal of Toxicology and Environmental Health: Part A65, 1307–1331.
17.
RiviereJ.E., BaynesR.E., BrooksJ.D., YeattsJ.L., & Monteiro-RiviereN.A. (2003). Percutaneous absorption of topical N,N-diethyl-m-toluamide (DEET): effects of exposure variables and coadministered toxicants. Journal of Toxicology and Environmental Health: Part A66, 133–151.
18.
MahmoudA., HaberlandA., DürrfeldM., HeydeckD., WagnerS., & Schäfer-KortingM. (2005). Cutaneous estradiol permeation, penetration and metabolism in pig and man. Skin Pharmacology and Physiology18, 27–35.
19.
WagnerS.M., NogueiraA.C., PaulM., HeydeckD., KlugS., & ChristB. (2003). The isolated nor-mothermic hemoperfused porcine forelimb as a test system for transdermal absorption studies. Journal of Artificial Organs6, 183–191.
20.
KietzmannM., LoscherW., ArensD., MaassP., & LubachD. (1993). The isolated perfused bovine udder as an in vitro model of percutaneous drug absorption. Skin viability and percutaneous absorption of dexamethasome, benzoyl peroxide, and etofenamate. Journal of Pharmacological and Toxicological Methods30, 75–84.
NetzlaffF., LehrC.M., WertzP.W., & SchaeferU.F. (2005). The human epidermis models EpiSkin, SkinEthic and EpiDerm: an evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. European Journal of Pharmaceutics and Biopharmaceutics60, 167–178.
23.
PonecM., BoelsmaE., GibbsS., & MommaasM. (2002). Characterization of reconstructed skin models. Skin Pharmacology and Applied Skin Physiology15, Suppl. 1, 4–17.
24.
LiebschM., TraueD., BarrabasC., SpielmannH., UphillP., WilkinsS., McPhersonJ.P., WiemannC., KaufmannT., RemmeleM., & HolzhütterH-G. (2000). The ECVAM prevalidation study on the use of EpiDerm for skin corrosivity testing. ATLA28, 371–401.
25.
SpielmannH., MullerL., AverbackD., BallsM., Brendler-SchwaabS., CastellJ.V., CurrenR., de SilvaO., GibbsN.K., LiebschM., LovellW.W., MerkH.F., NashJ.F., NeumannN.J., PapeW.J.W., UlrichP., & VohrH-W. (2000). The second ECVAM workshop on phototoxicity testing. The report and recommendations of ECVAM workshop 42. ATLA28, 777–814.
26.
LotteC., PatouilletC., ZaniniM., MessagerA., & RoguetR. (2002). Permeation and skin absorption: reproducibility of various industrial reconstructed human skin models. Skin Pharmacology and Applied Skin Physiology15, Suppl. 1, 18–30.
27.
DreherF., FouchardF., PatouilletC., AndrianM., SimonetJ.T., & Benech-KiefferF. (2002). Comparison of cutaneous bioavailability of cosmetic preparations containing caffeine or alpha-tocopherol applied on human skin models or human skin ex vivo at finite doses. Skin Pharmacology and Applied Skin Physiology12, Suppl. 1, 40–58.
28.
DreherF., PatouilletC., FouchardF., ZaniniM., MessagerA., RougetR., CottinM., LeclaireJ., & Beech-KiefferF. (2002). Improvement of the experimental setup to assess cutaneous bioavailability on human skin models: dynamic protocol. Skin Pharmacology and Applied Skin Physiology15, Suppl. 1, 31–39.
29.
GyslerA., KleuserB., SipplW., LangeK., KortingH.C., HöltjeH.D., & Schäfer-KortingM. (1999). Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharmacological Research16, 1386–1391.
30.
Santos MaiaC., MehnertW., SchallerM., KortingH., GyslerA., HaberlandA., & Schäfer-KortingM. (2002). Drug targeting by solid lipid nanoparticles for dermal use. Journal of Drug Targeting10, 489–495.
31.
SivaramakrishnanR., NakamuraC., MehnertW., KortingH.C., KramerK.D., & Schäfer-KortingM. (2004). Glucocorticoid entrapment into lipid carriers — characterisation by parelectric spectroscopy and influence on dermal uptake. Journal of Controlled Release97, 493–502.
32.
SchmookF.P., MeingassnerJ.G., & BillichA. (2001). Comparison of human skin or epidermis models with human and animal skin in in vitro percutaneous absorption. International Journal of Pharmaceutics215, 51–56.
33.
HaberlandA., SchreiberS., MaiaC.S., RübbelkeM.K., SchallerM., KortingH.C., KleuserB., SchimkeI., & Schäfer-KortingM. (2006). The impact of skin viability on drug metabolism and permeation-BSA toxicity on primary keratinocytes. Toxicology in Vitro20, 347–354.
34.
SchreiberS., MahmoudA., VuiaA., RübbelkeM.K., SchmidtE., SchallerM., KandarovaH., HaberlandA., SchaeferU.F., BockU., KortingH.C., LiebschM., & Schäfer-KortingM. (2005). Reconstructed epidermis versus human and animal skin in skin absorption studies. Toxicology in Vitro19, 813–822.
35.
NetzlaffF., KostkaK.H., LehrC.M., & SchaeferU.F. (2006). TEWL measurements as a routine method for evaluating the integrity of epidermis sheets in static Franz type diffusion cells in vitro. Limitations shown by transport data testing. European Journal of Pharmaceutics and Biopharmaceutics63, 44–50.
36.
KligmanA.M., & ChristophersE. (1963). Preparation of isolated sheets of human stratum corneum. Archives of Dermatology88, 702–705.
37.
DIN (1991). DIN ISO 5725-2: Genauigkeit (Richtigkeit und Präzision) von der Ermittlung der Wiederhole und Vergleichspräzision von festgelegten Messverfahren.Entwurf. Berlin, Germany: Beuth Verlag GmbH.
38.
SpielmannH., LiebschM., DöringB., & MoldenhauerF. (1994). First results of an EC/COLIPA validation project of in vitro phototoxicity testing methods. ALTEX11, 22–31.
39.
FentemJ.H. (1999). Validation of in vitro tests for skin corrosivity. ALTEX16, 150–153.
40.
FentemJ.H., & BothamP.A. (2002). ECVAM's activities in validating alternative tests for skin corrosion and irritation. ATLA30, Suppl. 2, 61–67.
41.
KandarovaH., LiebschM., GenschowE., GernerI., TraueD., SlawikB., & SpielmannH. (2004). Optimisation of the EpiDerm test protocol for the upcoming ECVAM validation study on in vitro skin irritation tests. ALTEX21, 107–114.
42.
WelssT., BasketterD.A., & SchröderK.R. (2004). In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicology in Vitro18, 231–243.
43.
AebyP., WyssC., BeckH., GriemP., SchefflerH., & GoebelC. (2004). Characterization of the sensitizing potential of chemicals by in vitro analysis of dendritic cell activation and skin penetration. Journal of Investigative Dermatology122, 1154–1164.
44.
JacobsJ.J., LeheC.L., CammansK.D., DasP.K., & ElliottG.R. (2004). Assessment of contact allergens by dissociation of irritant and sensitizing properties. Toxicology in Vitro18, 681–690.
45.
van der SandtJ.J.M., MaasW.J.M., van BurgstedenJ.A., SartorelliP., MontomoliL., LareseF., PayanJ-P., LimasetJ.C., CarmichaelP., KenyonS., RobinsonE., DickI., NilsenJ., SchallerK-H., KorinthG., CageS., WilkinsonS.C., & Williams FaithM. (2004). In vitro predictions of skin absorption of caffeine, testosterone and benzoic acid: a multicentre comparison study. Regulatory Toxicology and Pharmacology39, 271–281.
46.
SuhonenT., Pasonen-SeppänenS., KirjavainenM., TammiM., TammiR., & UrttiA. (2003). Epidermal cell culture model derived from rat keratinocytes with permeability characteristics comparable to human cadaver skin. European Journal of Pharmaceutical Sciences20, 107–113.
47.
BaynesR.E. (2004). In vitro dermal disposition of abamectin (avermectin B[1]) in livestock. Research in Veterinary Science76, 235–242.
48.
NavidiW.C., & BungeA.L. (2002). Uncertainty in measurements of dermal absorption of pesticides. Risk Analysis22, 1175–1182.
49.
GyslerA., LangeK., KortingH.C., & Schäfer-KortingM. (1997). Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharmacological Research Communications14, 793–797.
50.
COLIPA (1995). Cosmetic Ingredients: Guidelines for Percutaneous Absorption/penetration.6 pp. Brussels, Belgium: COLIPA.
51.
BosJ.D., & MeinardiM.M. (2000). The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology9, 165–169.
